What is Phage Lab?
Phage Lab is a biotechnology firm dedicated to combating bacterial challenges, particularly within the livestock industry, by developing precision bacteriophage treatments. This innovative approach aims to reduce the reliance on traditional antibiotics. The company leverages a sophisticated platform that integrates deep epidemiological diagnostics, informed by a decade of data collection, to create highly effective bacterial population control strategies. Headquartered in Santiago, Chile, with an international presence in Spain and Brazil, Phage Lab's mission is to provide personalized bacteriophage solutions for global bacterial issues.
How much funding has Phage Lab raised?
Phage Lab has raised a total of $11M across 1 funding round:
Other Financing Round
$11M
Other Financing Round (2024): $11M with participation from Nazca and Collaborative Fund
Key Investors in Phage Lab
Nazca
Nazca is an entity specializing in integrated solutions for Facility Management, Property Management, and Space as a Service, focusing on efficiency and innovation in building management.
Collaborative Fund
Collaborative Fund is a venture capital firm that provides capital and strategic support to entrepreneurs, with a history of early investments in prominent companies across various sectors.
What's next for Phage Lab?
The recent major strategic investment signals a pivotal growth phase for Phage Lab, likely enabling the company to scale its operations, expand its research and development capabilities, and further penetrate the livestock market. This capital infusion is expected to accelerate the commercialization of its precision bacteriophage treatments, positioning Phage Lab as a key player in sustainable bacterial management and antibiotic reduction strategies. The company's focus on data-driven diagnostics suggests a continued emphasis on technological advancement and market leadership.
See full Phage Lab company page
